二甲双胍治疗肝纤维化的研究进展。
Research progress of metformin in the treatment of liver fibrosis.
机构信息
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China.
Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, China.
出版信息
Int Immunopharmacol. 2023 Mar;116:109738. doi: 10.1016/j.intimp.2023.109738. Epub 2023 Jan 23.
Liver fibrosis is a disease with significant morbidity and mortality. It is a chronic pathological process characterized by an imbalance of extracellular matrix production and degradation in liver tissue. Metformin is a type of hypoglycemic biguanide drug, which can be used in the treatment of liver fibrosis, but its anti-fibrotic effect and mechanism of action are unclear. The purpose of this article is to review the research progress of metformin in the treatment of liver fibrosis and to provide a theoretical basis for its application in the treatment of liver fibrosis.
肝纤维化是一种具有显著发病率和死亡率的疾病。它是一种慢性病理过程，其特征在于肝组织中细胞外基质产生和降解的失衡。二甲双胍是一种降血糖双胍类药物，可用于治疗肝纤维化，但它的抗纤维化作用及其作用机制尚不清楚。本文旨在综述二甲双胍在治疗肝纤维化中的研究进展，为其在肝纤维化治疗中的应用提供理论依据。
Zotero 插件